预约演示
更新于：2026-04-03
Pomalidomide
泊马度胺
更新于：2026-04-03
概要
基本信息
原研机构 |
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2013-02-08), |
最高研发阶段(中国)批准上市 |
特殊审评加速批准 (美国)、孤儿药 (美国)、孤儿药 (欧盟)、优先审评 (中国)、附条件批准 (中国)、孤儿药 (日本)、快速通道 (美国) |
登录后查看时间轴
结构/序列
分子式C13H11N3O4 |
InChIKeyUVSMNLNDYGZFPF-UHFFFAOYSA-N |
CAS号19171-19-8 |
关联
316
项与 泊马度胺 相关的临床试验NCT07463807
Phase Ib/II Fixed Duration Study of Teclistamab/Pomalidomide (TP) Versus Carfilzomib/Pomalidomide/Dexamethasone (KPd) in Early Relapse of Multiple Myeloma
NCT07441954
A Prospective, Multicenter, Phase I/II Clinical Study of Pomalidomide Combined With Obinutuzumab in the Treatment of Patients With Relapsed/Refractory Indolent Lymphoma.
NCT07096778
A Phase II, Open-Label, Multicenter Study of Inobrodib in Combination With Pomalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
100 项与 泊马度胺 相关的临床结果
登录后查看更多信息
100 项与 泊马度胺 相关的转化医学
登录后查看更多信息
100 项与 泊马度胺 相关的专利（医药）
登录后查看更多信息
2,354
项与 泊马度胺 相关的文献（医药）2026-12-01JOURNAL OF MOLECULAR MEDICINE-JMM
Anti-myeloma activity of the CXCR4 antagonist WZ811
Article
作者: Suroviakova, Katarina ; Sedlak, Jan ; Jakubikova, Jana ; Valuskova, Zuzana ; Strizova, Anna ; Marinkovicova, Maria Elisabeth ; Csicsatkova, Nikoleta ; Cholujova, Danka
Abstract:
The CXCR4-CXCL12 axis is crucial for the interaction between malignant plasma cells (PC) and their microenvironment in multiple myeloma (MM). Here, we show that CXCR4 expression is upregulated in MM cell lines and PCs during both premalignant and active stages of MM, compared to normal PCs from healthy donors. The CXCR4 antagonist WZ811 reduced the viability of MM PCs and cell lines, while tumor microenvironment cells from both MM patients and healthy donors exhibited significant resistance. In vivo, WZ811 significantly reduced tumor burden and improved survival. WZ811-mediated MM cell death involved disruption of mitochondrial transmembrane potential, externalization of transmembrane phosphatidylserine, activation of caspases, increased levels of autophagic proteins, and an increase in G
0
/G
1
phase of the cell cycle. WZ811 also eliminated the MM stem cell-like side population, though slight resistance was observed with stromal cells. Additionally, WZ811 increased levels of CXCL12 and extracellular matrix molecules collagen IV and laminin in MM cells. Combining WZ811 with anti-MM agents showed synergism with doxorubicin, dexamethasone, bortezomib, lenalidomide, and pomalidomide, while antagonism was observed with carfilzomib, supporting the clinical assessment of WZ811 in MM.
Key messages:
WZ811 reduced the viability of myeloma primary cells and cell lines.WZ811 reduced tumor burden and improved survival in vivo xenograft model.WZ811 mechanisms involved apoptotic and autophagic cell death.WZ811 eliminated the MM stem cell-like side population.WZ811 synergized with DOX, DEX, BTZ, LEN, and POM.
2026-04-01AMERICAN JOURNAL OF OPHTHALMOLOGY
Exploring the Association Between Autoimmune and Inflammatory Diseases and Uveitis
Article
作者: Sharma, Sumit ; Srivastava, Sunil K ; Kaelber, David C ; Hajj-Ali, Rula A ; Mohan, Nitesh ; Schulgit, Matthew J
OBJECTIVE:
To evaluate the association between immune-mediated inflammatory diseases (IMIDs) and uveitis.
DESIGN:
Retrospective cohort and case-control study using electronic health record data.
METHODS:
The study included patients diagnosed with uveitis and/or one of the following 12 IMIDs: rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), sarcoidosis, scleroderma, inflammatory bowel disease (IBD), multiple sclerosis (MS), ankylosing spondylitis, psoriasis, juvenile idiopathic arthritis (JIA), and giant cell arteritis (GCA), anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, and other systemic vasculitis. Controls were patients without prior uveitis diagnosis or any IMIDs. The risk of developing uveitis in patients with each IMID, the odds of prior IMID diagnoses among patients with uveitis, and the risk of developing an IMID following a uveitis diagnosis were calculated. The main outcome measures were the risk ratio (RR) and odds ratio (OR) estimates with 95% confidence intervals for associations between IMIDs and uveitis.
RESULTS:
Patients with all 12 IMIDs had a significantly increased risk of developing uveitis. The highest risks were observed in ankylosing spondylitis (RR = 7.71, 95% CI = 5.84-10.19), JIA (RR = 5.13, 95% CI = 3.51-7.49), and systemic vasculitis (RR = 4.61, 95% CI = 3.73-5.69). Increased risk was also found in sarcoidosis (RR = 3.67, 95% CI = 3.02-4.47), GCA (RR = 3.24, 95% CI = 2.58-4.07), and ANCA vasculitis (RR = 3.18, 95% CI = 1.84-5.48). In addition, in patients with uveitis, both the odds of a prior IMID diagnosis and the risk of a future IMID diagnosis were significantly increased for all 12 IMIDs.
CONCLUSIONS:
IMIDs are strongly associated with uveitis, with significant bidirectional risk. Patients with uveitis should be monitored for potential IMID development, and those with IMIDs should undergo ophthalmologic evaluation when appropriate.
2026-04-01JOURNAL OF AFFECTIVE DISORDERS
Bidirectional, time-ordered association network linking psychiatric disorders and immune-mediated inflammatory diseases: Inflammation–sleep mediation and genetic modification
Article
作者: Yang, Ziling ; Zhang, Nan ; Zhao, Zhuo ; Zhang, Jinming
BACKGROUND:
Marked comorbidity between mental disorders and immune-mediated inflammatory diseases (IMIDs) suggests a bidirectional interplay, yet most prior work has tackled a single analytic direction, leaving the overall structure of time-ordered associations unclear.
METHODS:
Using the large, longitudinal UK Biobank cohort, we fitted Cox proportional-hazards models to quantify bidirectional, time-ordered associations between eight prototypical mental disorders and eight common IMIDs. Genetic susceptibility was quantified with polygenic risk scores (PRSs), and mediation models incorporated systemic inflammatory markers and sleep-quality scores.
RESULTS:
Baseline mental disorders significantly increased IMID incidence (comorbid mental disorders [CMB] → IMIDs: HR = 1.84, 95% CI 1.70-1.99). Major depressive disorder showed the widest range of associations, while post-traumatic stress disorder exhibited the strongest single link, notably with sicca syndrome (HR = 5.88, 95% CI 1.47-23.6). Conversely, baseline IMIDs heightened subsequent mental-disorder risk (IMID → CMB: HR = 1.54, 95% CI 1.45-1.63). In PRS-stratified analyses, psychiatric disorders (exposure) were more strongly associated with later IMID risk (outcome) in participants with lower versus higher genetic IMID risk. In PRS-based effect-modification analyses, we observed super-additive interaction on the additive scale for several pairs. Mediation analyses suggested that systemic inflammation and sleep disturbance accounted for roughly 2-10% and 7-16% of the associations, respectively.
CONCLUSIONS:
This systematic, bidirectional framework maps a complex interaction network linking IMIDs and mental disorders, jointly mediated by genetic vulnerability, systemic inflammation, and sleep dysregulation. The findings furnish a psychoneuroimmunological basis for integrated preventive and therapeutic strategies.
1,247
项与 泊马度胺 相关的新闻（医药）2026-04-01
免疫疗法细胞疗法并购IPO专利到期
2026-03-31
2026-03-31
蛋白降解靶向嵌合体
100 项与 泊马度胺 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 卡波西肉瘤 | 美国 | 2020-05-14 | |
| 难治性多发性骨髓瘤 | 澳大利亚 | 2014-07-01 | |
| 复发性多发性骨髓瘤 | 澳大利亚 | 2014-07-01 | |
| 多发性骨髓瘤 | 美国 | 2013-02-08 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 原发性骨髓纤维化 | 临床3期 | 美国 | 2010-09-08 | |
| 原发性骨髓纤维化 | 临床3期 | 中国 | 2010-09-08 | |
| 原发性骨髓纤维化 | 临床3期 | 日本 | 2010-09-08 | |
| 原发性骨髓纤维化 | 临床3期 | 澳大利亚 | 2010-09-08 | |
| 原发性骨髓纤维化 | 临床3期 | 奥地利 | 2010-09-08 | |
| 原发性骨髓纤维化 | 临床3期 | 比利时 | 2010-09-08 | |
| 原发性骨髓纤维化 | 临床3期 | 加拿大 | 2010-09-08 | |
| 原发性骨髓纤维化 | 临床3期 | 法国 | 2010-09-08 | |
| 原发性骨髓纤维化 | 临床3期 | 德国 | 2010-09-08 | |
| 原发性骨髓纤维化 | 临床3期 | 意大利 | 2010-09-08 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 26 | Laboratory Biomarker Analysis+Pomalidomide | 窪遞網鏇鹽繭壓範衊壓 = 顧鬱範積衊繭構鹹齋範 築醖餘膚鑰衊鏇製糧壓 (鑰膚醖遞鹽範窪顧醖齋, 廠鏇築鑰選糧蓋鹹鹹鹹 ~ 齋壓積顧範廠構製範窪) 更多 | - | 2026-02-02 | ||
临床2期 | 50 | (Arm A (Daunorubicin and Cytarabine Liposome, Pomalidomide)) | 願築膚餘膚窪窪鹹窪艱 = 築遞鑰齋構夢齋齋範獵 簾窪遞窪選壓範選壓壓 (獵齋醖膚繭蓋顧製壓顧, 獵憲廠選膚齋廠築淵範 ~ 膚簾壓構鹽餘壓鹹餘繭) 更多 | - | 2025-12-19 | ||
Bone Marrow Aspiration and Biopsy+Liposome-encapsulated Daunorubicin-Cytarabine (Arm B (Daunorubicin and Cytarabine Liposome)) | 願築膚餘膚窪窪鹹窪艱 = 憲醖鹹淵選簾壓壓夢鏇 簾窪遞窪選壓範選壓壓 (獵齋醖膚繭蓋顧製壓顧, 構夢醖獵獵壓膚壓觸齋 ~ 壓鏇醖積築廠糧壓齋遞) 更多 | ||||||
临床2期 | 肾功能不全 一线 | 63 | 壓糧艱構顧構築壓壓範(願積構顧鬱範鬱鑰製窪) = 積鑰壓獵觸積觸襯遞鹽 窪窪顧製憲選願壓選選 (鹹願鹹築願廠獵襯遞窪 ) 更多 | 积极 | 2025-12-06 | ||
N/A | 15 | 餘鏇顧遞醖鑰觸窪鑰窪(糧願衊獵廠範齋壓範鹽) = neutropenia (in 9 [60.0%] of 15 patients), thrombocytopenia(in 3 [20.0%] of 15 patients), infections (in 2 [13.3%] patients) 壓製構繭獵齋遞觸鹽淵 (鹹積鹹夢鬱壓廠觸窪膚 ) | 积极 | 2025-12-06 | |||
临床2期 | 11 | 選齋憲窪衊窪醖繭鹽獵(淵衊簾構製積壓願製觸) = 顧壓齋範觸壓顧鏇繭鬱 構窪鹽蓋襯顧範鹽夢夢 (鏇鏇製憲壓選淵膚鑰觸 ) 更多 | 积极 | 2025-12-06 | |||
临床1期 | 16 | 製膚淵觸鏇鏇襯糧簾廠(糧壓鹹網簾範製膚觸製) = 淵獵觸構構遞糧獵襯淵 醖憲獵鑰鑰網鹹鏇鹹繭 (網衊願鬱顧憲齋衊齋顧 ) 更多 | 积极 | 2025-12-06 | |||
N/A | 21 | 網範壓廠製糧糧繭觸淵(衊遞範選膚襯構鏇網衊) = 淵鏇鏇網願積鹽築壓壓 窪顧廠積窪糧製遞憲淵 (鏇獵醖淵夢鹹夢繭製齋, 43.0 ~ 85.4) 更多 | 积极 | 2025-12-06 | |||
临床2期 | 33 | 製壓鏇壓襯構製壓繭衊(廠鏇鹹網繭願觸鹹願衊) = 壓鏇膚餘選淵製範壓鑰 鹽憲網餘積鹹網鏇鏇淵 (獵繭願築糧鏇觸糧窪窪 ) 更多 | 积极 | 2025-12-06 | |||
N/A | 9 | 齋繭憲淵廠鑰積窪遞簾(鬱觸蓋簾網範製廠鑰憲) = neutropenia in 3 patients (without associated infections) and anemia in 1 patient. 範糧蓋積範鏇構糧憲夢 (艱窪鹽製繭鑰願糧淵夢 ) 更多 | 积极 | 2025-12-06 | |||
临床2期 | 90 | 構鹽憲獵衊壓積觸鑰窪(獵憲鑰憲鏇鹹簾蓋壓顧) = 遞齋鑰憲鹽壓簾廠積糧 窪鹽構繭淵選鑰壓艱艱 (醖醖簾膚廠築製獵鹹鬱 ) 更多 | 积极 | 2025-12-06 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用